Functional activity of new C-terminal cyclic-neurotensin fragment analogs

Neurotensin (NT, pGlu-Leu-Tyr-Glu-Asn-Lys-Pro-Arg-Arg-Pro-Tyr-Ile-Leu) is a tridecapeptide that displays a wide spectrum of biological actions. Cyclic derivatives of a hexapeptide NT [(8–13)] (NαMeArg-Lys-Pro-Trp-Tle-Leu, Tle = tert-leucine) were designed and prepared by a combination of solution an...

Full description

Saved in:
Bibliographic Details
Published in:Neuropeptides (Edinburgh) Vol. 30; no. 3; pp. 213 - 218
Main Authors: Akunne, H.C, Darling, S, Zoski, K, Sefler, A.M, He, J.X, Sawyer, T.K, Pugsley, T.A, Cody, W.L
Format: Journal Article
Language:English
Published: Oxford Elsevier Ltd 01-06-1996
Elsevier
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Neurotensin (NT, pGlu-Leu-Tyr-Glu-Asn-Lys-Pro-Arg-Arg-Pro-Tyr-Ile-Leu) is a tridecapeptide that displays a wide spectrum of biological actions. Cyclic derivatives of a hexapeptide NT [(8–13)] (NαMeArg-Lys-Pro-Trp-Tle-Leu, Tle = tert-leucine) were designed and prepared by a combination of solution and solid-phase peptide synthetic methodologies. As reported previously, several analogs possessed nanomolar binding affinities for NT receptors in newborn (10-day-old) mouse brain membrane preparations. In this study, we determined the functional ability of these analogs to mobilize intracellular free calcium, [Ca 2+] i, in HT-29 cells (human colonic adenocarcinoma). Of greatest interest were the cyclic compounds 2, 6 and 9 that had K i values of 0.19, 3.50 and 4.18 μM for [ 3H]NT labeled receptors in the HT-29 cell membrane assay, respectively. In the functional assay, compounds 2 and 6 mobilized [Ca 2+] with EC 50 values of 0.13 and 20 μM, respectively. In comparison, Compound 9 blocked the NT-induced mobilization of [Ca 2+] i, with an IC 50 of 1.70 μM. The present findings indicate that small molecule cyclic analogs, that possess functional activity, can be designed and may have therapeutic utility in the treatment of schizophrenia and possibly other neurological disorders.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ObjectType-Article-1
ObjectType-Feature-2
ISSN:0143-4179
1532-2785
DOI:10.1016/S0143-4179(96)90066-9